The Alliance for Regenerative Medicine Announces 2020 Virtual Fly-In, Connecting Sector Stakeholders with Congressional Representatives Amidst the COVID-19 Pandemic

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Washington, DC, May 20, 2020 — via NEWMEDIAWIRE — The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced that it will be holding its annual Legislative Fly-In today. This event, which has been remodeled to take place virtually, enables ARM members to advocate on Capitol Hill for legislative support of gene and cellular therapies and other regenerative medicines.

More than 120 ARM members are participating in the event, making this year ARM’s largest Fly-In to date. Participants will form 24 state delegations to meet with Members of Congress via video calls and teleconferencing systems. The meetings will focus on the immense near-term potential of gene and cell therapies and the need for legislation that supports patient access to these life-saving treatments.

Specifically, Fly-In participants will be asking Members of Congress to remove legislative barriers to the adoption of value-based payment models for gene and cell therapies. These therapies, which can provide a durable and potentially curative therapeutic effect, often with only a single administration, provide a profound benefit to patients and may result in cost-savings to the healthcare system in the medium to long term. However, existing reimbursement mechanisms have difficulty absorbing the upfront cost of these therapies.

To address these challenges, ARM works with its members and policymakers to promote the adoption of innovative payment models for regenerative medicines. These models include annuities, which would allow payors to amortize the cost of therapies over a longer period of time, as well as performance-based models, which tie the payment for therapies to predetermined health outcomes. 

For more information on the event or ARM’s legislative goals, please contact Kaitlyn (Donaldson) Dupont at [email protected]

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors, and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org

Kaitlyn (Donaldson) Dupont 8037278346 [email protected]

Primary Logo